{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-005110","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.955210+00:00","generated_at":"2026-06-17T09:16:05.679074+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NeuroBo reports FY2022 net loss $14.0M; cash $33.4M; pipeline shift to cardiometabolic","bullets":["Net loss of $14.0M ($5.43 per share) vs $15.3M ($19.81 per share) in FY2021.","Cash and equivalents $33.4M as of Dec 31, 2022, up from $16.4M; runway into 2024.","R&D expenses fell to $2.8M from $6.5M due to reduced clinical activity and drug manufacturing.","Pipeline focus: DA-1241 phase 2a NASH study starts Q3 2023; DA-1726 IND/phase 1a expected H1 2024.","Legacy programs (ANA001, NB-01, NB-02, Gemcabene) to be licensed or acquired."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-005110","json":"https://secwatch.observer/filing/0001558370-23-005110.json","markdown":"https://secwatch.observer/filing/0001558370-23-005110.md","text":"https://secwatch.observer/filing/0001558370-23-005110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837023005110/0001558370-23-005110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837023005110/nrbo-20230330x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:16:05.679074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a14e5e45575b6563c0dbfeeab9c9417b9d067dd7","claim":"MetaVia Inc. reported year ended December 31, 2022 results: net income Net Loss for the year ended December 31, 2022 was $14.0 million, EPS $5.43 per basic and diluted share.","evidence_excerpt":"Net Loss for the year ended December 31, 2022 was $14.0 million, or $ 5.43 per basic and diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000155837023005110/0001558370-23-005110-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Net income","value":"Net Loss for the year ended December 31, 2022 was $14.0 million"},{"label":"EPS","value":"$5.43 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}